Compare MKTW & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKTW | EVAX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 31.9M |
| IPO Year | 2020 | 2020 |
| Metric | MKTW | EVAX |
|---|---|---|
| Price | $17.58 | $4.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $11.67 |
| AVG Volume (30 Days) | 24.9K | ★ 30.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | ★ 1183.33 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $512,403,000.00 | N/A |
| Revenue This Year | $1.52 | N/A |
| Revenue Next Year | $4.55 | $328.20 |
| P/E Ratio | $7.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.65 | $1.42 |
| 52 Week High | $21.74 | $12.15 |
| Indicator | MKTW | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 52.07 |
| Support Level | $16.06 | $2.64 |
| Resistance Level | $20.62 | $4.62 |
| Average True Range (ATR) | 0.87 | 0.32 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 77.84 | 30.71 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.